Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. Common Stock (RAPP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rapp · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Rapport Therapeutics, Inc. Common Stock (RAPP) measures how much investors pay for each dollar of the company's trailing earnings. RAPP's current PE ratio of N/A is calculated by dividing its stock price of $36.49 by its TTM earnings per share of -$2.27.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2022 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Rapport Therapeutics, Inc. Common StockYou RAPP | $1.3B | N/A | — | -$2.27 |
 AnaptysBio, Inc. ANAB | $2.2B | N/A | — | -$0.48 |
 BridgeBio Oncology Therapeutics Inc. BBOT | $625M | N/A | — | -$4.30 |
 Kodiak Sciences Inc. KOD | $1.6B | N/A | — | -$4.32 |
 Mind Medicine (MindMed) Inc. MNMD | $1.6B | N/A | — | -$2.06 |
 Nurix Therapeutics, Inc. NRIX | $1.3B | N/A | — | -$3.05 |
 Oculis Holding AG OCS | $607M | N/A | — | -$1.81 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.37 | — | |
2024-12-31 FY2024 | — | $-3.78 | — | |
2023-12-31 FY2023 | — | $-1.92 | — | |
2022-12-31 FY2022 | — | $-0.53 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Rapport Therapeutics, Inc. Common Stock (RAPP) measures how much investors pay for each dollar of the company's trailing earnings. RAPP's current PE ratio of N/A is calculated by dividing its stock price of $36.49 by its TTM earnings per share of -$2.27.
Frequently asked questions
RAPP pe ratio · 6 questionsRAPP's current PE ratio is N/A as of 2026-06-08, based on a stock price of $36.49 and TTM EPS of -$2.27. Data sourced from Financial Modeling Prep via RAPP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Rapport Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08